It is revealed that Pfizer and BioNTech vaccine was able to fight the Brazil variant of Covid.
Scientists tested the blood of persons who had taken the jab. The experiment found it did well on a laboratory-made virus alike to the one found in Brazil.
The New England Journal of Medicine has told the research stating it could calm the P.1 variant’s fears. The virus, however, is found to spread faster than other types of Covid virus since it began in South America.
Scientists of the two medical companies and the University of Texas created a version of the virus. The experiment resulted in the same spike protein mutations as the P.1 variant.
This is what was tested in the blood of those who were vaccinated. The spike protein is the section of the virus used to get into human cells. Thus, vaccines’ work is to target these mutations.
Moreover, it is found that the antibodies from the blood were effective in neutralising the test virus.
Other studies show that Pfizer and BioNTech jab are working on the virus’s variants in the UK and South Africa. However, the South African variant may lessen the guarding antibodies spurred by the vaccine.
It believes its current insulation is highly likely to shield upon the S. African variant still.
However, the pharmaceutical giant is intending to test the third booster of its jab. Moreover, creating a version of the drug specially designed to fight the new variant.